N-(2,3-dihydro-1H-inden-5-yl)-2-(4-hydroxyphenyl)acetamide | 321853-28-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,3-dihydro-1H-inden-5-yl)-2-(4-hydroxyphenyl)acetamide
• CAS: 321853-28-5
• 化学式: C₁₇H₁₇NO₂
• 分子量: 267.327
• InChiKey: QTOMIDYVTFNRAN-UHFFFAOYSA-N

物化性质

• 熔点：
  157-158°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(2,3-dihydro-1H-inden-5-yl)-2-(4-hydroxyphenyl)acetamide 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[4-[2-(2,3-dihydro-1H-inden-5-ylamino)-2-oxoethyl]phenoxy]butanoic acid
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Chiral Allosteric Modifiers of Hemoglobin

  摘要：

  A series of allosteric effecters of hemoglobin, 2-(aryloxy)-2-alkanoic acids, was prepared to investigate the effect of the stereocenter on allosteric activity. The chiral analogues were based on the lead compound, RSR13 (3b), with different alkyl/alkanoic and cycloalkyl/cycloalkanoic groups positioned at the acidic chiral center. Of the 23 racemic molecules synthesized, 5 were selected for resolution based on structure-activity relationships. One chiral analogue, (-)( 1R,2R)-1-[4-[[(3,5 -dimethylanilino)carbonyl]methyl]phenoxy]-2-methylcyclopentanecarboxylic acid (11), exhibited greater in vitro activity in hemoglobin solutions than its antipode, racemate, and RSR13. Compound (-)-(LR,2R)-11 was equipotent with RSR13 in whole blood, is a candidate for in vivo animal studies, and if efficacious and safe has a potential for use in humans. In general, it was found that chirality affects allosteric effector activity with measurable differences observed between enantiomers and the racemates.

  DOI：

  10.1021/jm000199q
• 作为产物：
  描述：

  对羟基苯乙酸 、 5-氨基茚旦 以 xylene 为溶剂， 反应 72.0h， 以90%的产率得到N-(2,3-dihydro-1H-inden-5-yl)-2-(4-hydroxyphenyl)acetamide
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Chiral Allosteric Modifiers of Hemoglobin

  摘要：

  A series of allosteric effecters of hemoglobin, 2-(aryloxy)-2-alkanoic acids, was prepared to investigate the effect of the stereocenter on allosteric activity. The chiral analogues were based on the lead compound, RSR13 (3b), with different alkyl/alkanoic and cycloalkyl/cycloalkanoic groups positioned at the acidic chiral center. Of the 23 racemic molecules synthesized, 5 were selected for resolution based on structure-activity relationships. One chiral analogue, (-)( 1R,2R)-1-[4-[[(3,5 -dimethylanilino)carbonyl]methyl]phenoxy]-2-methylcyclopentanecarboxylic acid (11), exhibited greater in vitro activity in hemoglobin solutions than its antipode, racemate, and RSR13. Compound (-)-(LR,2R)-11 was equipotent with RSR13 in whole blood, is a candidate for in vivo animal studies, and if efficacious and safe has a potential for use in humans. In general, it was found that chirality affects allosteric effector activity with measurable differences observed between enantiomers and the racemates.

  DOI：

  10.1021/jm000199q

文献信息

• Synthesis and Structure−Activity Relationships of Chiral Allosteric Modifiers of Hemoglobin
  作者：Melissa Phelps Grella、Richmond Danso-Danquah、Martin K. Safo、Gajanan S. Joshi、Jean Kister、Michael Marden、Stephen J. Hoffman、Donald J. Abraham

  DOI：10.1021/jm000199q

  日期：2000.12.1

  A series of allosteric effecters of hemoglobin, 2-(aryloxy)-2-alkanoic acids, was prepared to investigate the effect of the stereocenter on allosteric activity. The chiral analogues were based on the lead compound, RSR13 (3b), with different alkyl/alkanoic and cycloalkyl/cycloalkanoic groups positioned at the acidic chiral center. Of the 23 racemic molecules synthesized, 5 were selected for resolution based on structure-activity relationships. One chiral analogue, (-)( 1R,2R)-1-[4-[[(3,5 -dimethylanilino)carbonyl]methyl]phenoxy]-2-methylcyclopentanecarboxylic acid (11), exhibited greater in vitro activity in hemoglobin solutions than its antipode, racemate, and RSR13. Compound (-)-(LR,2R)-11 was equipotent with RSR13 in whole blood, is a candidate for in vivo animal studies, and if efficacious and safe has a potential for use in humans. In general, it was found that chirality affects allosteric effector activity with measurable differences observed between enantiomers and the racemates.